CD38 and Miyoshi myopathy: Introduction of the anti-CD38 monoclonal antibody daratumumab has had a major impact on the frontline treatment landscape of MM, and daratumumab-based quadruplets including Dara-VRd and Dara-VTd are emerging as the new SOC, with substantial improvements in efficacy outcomes observed, versus triplet therapy.2,12